{"id":19181,"date":"2024-08-12T19:57:30","date_gmt":"2024-08-12T22:57:30","guid":{"rendered":"https:\/\/ptbr.idor.org\/pesquisa\/ensaiosclinicos\/imc-f106c-101-tumores-solidos\/"},"modified":"2024-08-12T19:57:30","modified_gmt":"2024-08-12T22:57:30","slug":"imc-f106c-101-tumores-solidos","status":"publish","type":"ensaio_clinico","link":"https:\/\/www.rededorsaoluiz.com.br\/instituto\/idor\/pesquisa\/ensaiosclinicos\/imc-f106c-101-tumores-solidos\/","title":{"rendered":"IMC-F106C-101 \u2013 Tumores s\u00f3lidos"},"content":{"rendered":"<div>\n<div><u data-olk-copy-source=\"MessageBody\">Carcinoma n\u00e3o pequenas c\u00e9lulas de pulm\u00e3o<\/u><\/div>\n<div>Refrat\u00e1rio a pelo menos 1 linha de quimioterapia (incluindo platina, imunoterapia e terapia alvo EGFR e ALK, se aplic\u00e1vel).<\/div>\n<div>&nbsp;<\/div>\n<div><u>Carcinoma seroso de ov\u00e1rio<\/u><\/div>\n<div>Refrat\u00e1rio a pelo menos 2 linhas de quimioterapia (incluindo platina, Bevacizumabe&nbsp;e inibidor de PARP, se aplic\u00e1vel);<\/div>\n<div>Status de BRCA deve ser conhecido.<\/div>\n<\/div>\n<p>Clinical Trials: NCT04262466<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Carcinoma n\u00e3o pequenas c\u00e9lulas de pulm\u00e3o Refrat\u00e1rio a pelo menos 1 linha de quimioterapia (incluindo platina, imunoterapia e terapia alvo EGFR e ALK, se aplic\u00e1vel). &nbsp; Carcinoma seroso de ov\u00e1rio Refrat\u00e1rio a pelo menos 2 linhas de quimioterapia (incluindo platina, Bevacizumabe&nbsp;e inibidor de PARP, se aplic\u00e1vel); Status de BRCA deve ser conhecido. Clinical Trials: NCT04262466<\/p>\n","protected":false},"featured_media":0,"template":"","meta":{"_acf_changed":false},"class_list":["post-19181","ensaio_clinico","type-ensaio_clinico","status-publish","hentry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>IMC-F106C-101 \u2013 Tumores s\u00f3lidos - IDOR - Instituto D&#039;Or de Pesquisa e Ensino<\/title>\n<link rel=\"canonical\" href=\"https:\/\/www.rededorsaoluiz.com.br\/instituto\/idor\/pesquisa\/ensaiosclinicos\/imc-f106c-101-tumores-solidos\/\" \/>\n<meta property=\"og:locale\" content=\"pt_BR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"IMC-F106C-101 \u2013 Tumores s\u00f3lidos - IDOR - Instituto D&#039;Or de Pesquisa e Ensino\" \/>\n<meta property=\"og:description\" content=\"Carcinoma n\u00e3o pequenas c\u00e9lulas de pulm\u00e3o Refrat\u00e1rio a pelo menos 1 linha de quimioterapia (incluindo platina, imunoterapia e terapia alvo EGFR e ALK, se aplic\u00e1vel). &nbsp; Carcinoma seroso de ov\u00e1rio Refrat\u00e1rio a pelo menos 2 linhas de quimioterapia (incluindo platina, Bevacizumabe&nbsp;e inibidor de PARP, se aplic\u00e1vel); Status de BRCA deve ser conhecido. Clinical Trials: NCT04262466\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.rededorsaoluiz.com.br\/instituto\/idor\/pesquisa\/ensaiosclinicos\/imc-f106c-101-tumores-solidos\/\" \/>\n<meta property=\"og:site_name\" content=\"IDOR - Instituto D&#039;Or de Pesquisa e Ensino\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.rededorsaoluiz.com.br\\\/instituto\\\/idor\\\/pesquisa\\\/ensaiosclinicos\\\/imc-f106c-101-tumores-solidos\\\/\",\"url\":\"https:\\\/\\\/www.rededorsaoluiz.com.br\\\/instituto\\\/idor\\\/pesquisa\\\/ensaiosclinicos\\\/imc-f106c-101-tumores-solidos\\\/\",\"name\":\"IMC-F106C-101 \u2013 Tumores s\u00f3lidos - IDOR - Instituto D&#039;Or de Pesquisa e Ensino\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ptbr.idor.org\\\/#website\"},\"datePublished\":\"2024-08-12T22:57:30+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.rededorsaoluiz.com.br\\\/instituto\\\/idor\\\/pesquisa\\\/ensaiosclinicos\\\/imc-f106c-101-tumores-solidos\\\/#breadcrumb\"},\"inLanguage\":\"pt-BR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.rededorsaoluiz.com.br\\\/instituto\\\/idor\\\/pesquisa\\\/ensaiosclinicos\\\/imc-f106c-101-tumores-solidos\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.rededorsaoluiz.com.br\\\/instituto\\\/idor\\\/pesquisa\\\/ensaiosclinicos\\\/imc-f106c-101-tumores-solidos\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"In\u00edcio\",\"item\":\"https:\\\/\\\/ptbr.idor.org\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ensaios Cl\u00ednicos\",\"item\":\"https:\\\/\\\/ptbr.idor.org\\\/pesquisa\\\/ensaiosclinicos\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"IMC-F106C-101 \u2013 Tumores s\u00f3lidos\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/ptbr.idor.org\\\/#website\",\"url\":\"https:\\\/\\\/ptbr.idor.org\\\/\",\"name\":\"IDOR - Instituto D&#039;Or de Pesquisa e Ensino\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/ptbr.idor.org\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"pt-BR\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"IMC-F106C-101 \u2013 Tumores s\u00f3lidos - IDOR - Instituto D&#039;Or de Pesquisa e Ensino","canonical":"https:\/\/www.rededorsaoluiz.com.br\/instituto\/idor\/pesquisa\/ensaiosclinicos\/imc-f106c-101-tumores-solidos\/","og_locale":"pt_BR","og_type":"article","og_title":"IMC-F106C-101 \u2013 Tumores s\u00f3lidos - IDOR - Instituto D&#039;Or de Pesquisa e Ensino","og_description":"Carcinoma n\u00e3o pequenas c\u00e9lulas de pulm\u00e3o Refrat\u00e1rio a pelo menos 1 linha de quimioterapia (incluindo platina, imunoterapia e terapia alvo EGFR e ALK, se aplic\u00e1vel). &nbsp; Carcinoma seroso de ov\u00e1rio Refrat\u00e1rio a pelo menos 2 linhas de quimioterapia (incluindo platina, Bevacizumabe&nbsp;e inibidor de PARP, se aplic\u00e1vel); Status de BRCA deve ser conhecido. Clinical Trials: NCT04262466","og_url":"https:\/\/www.rededorsaoluiz.com.br\/instituto\/idor\/pesquisa\/ensaiosclinicos\/imc-f106c-101-tumores-solidos\/","og_site_name":"IDOR - Instituto D&#039;Or de Pesquisa e Ensino","twitter_card":"summary_large_image","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.rededorsaoluiz.com.br\/instituto\/idor\/pesquisa\/ensaiosclinicos\/imc-f106c-101-tumores-solidos\/","url":"https:\/\/www.rededorsaoluiz.com.br\/instituto\/idor\/pesquisa\/ensaiosclinicos\/imc-f106c-101-tumores-solidos\/","name":"IMC-F106C-101 \u2013 Tumores s\u00f3lidos - IDOR - Instituto D&#039;Or de Pesquisa e Ensino","isPartOf":{"@id":"https:\/\/ptbr.idor.org\/#website"},"datePublished":"2024-08-12T22:57:30+00:00","breadcrumb":{"@id":"https:\/\/www.rededorsaoluiz.com.br\/instituto\/idor\/pesquisa\/ensaiosclinicos\/imc-f106c-101-tumores-solidos\/#breadcrumb"},"inLanguage":"pt-BR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.rededorsaoluiz.com.br\/instituto\/idor\/pesquisa\/ensaiosclinicos\/imc-f106c-101-tumores-solidos\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.rededorsaoluiz.com.br\/instituto\/idor\/pesquisa\/ensaiosclinicos\/imc-f106c-101-tumores-solidos\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"In\u00edcio","item":"https:\/\/ptbr.idor.org\/"},{"@type":"ListItem","position":2,"name":"Ensaios Cl\u00ednicos","item":"https:\/\/ptbr.idor.org\/pesquisa\/ensaiosclinicos\/"},{"@type":"ListItem","position":3,"name":"IMC-F106C-101 \u2013 Tumores s\u00f3lidos"}]},{"@type":"WebSite","@id":"https:\/\/ptbr.idor.org\/#website","url":"https:\/\/ptbr.idor.org\/","name":"IDOR - Instituto D&#039;Or de Pesquisa e Ensino","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ptbr.idor.org\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"pt-BR"}]}},"_links":{"self":[{"href":"https:\/\/www.rededorsaoluiz.com.br\/instituto\/idor\/wp-json\/wp\/v2\/ensaio_clinico\/19181","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.rededorsaoluiz.com.br\/instituto\/idor\/wp-json\/wp\/v2\/ensaio_clinico"}],"about":[{"href":"https:\/\/www.rededorsaoluiz.com.br\/instituto\/idor\/wp-json\/wp\/v2\/types\/ensaio_clinico"}],"wp:attachment":[{"href":"https:\/\/www.rededorsaoluiz.com.br\/instituto\/idor\/wp-json\/wp\/v2\/media?parent=19181"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}